Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to SARS-CoV-2 in individuals aged 20 years and older – third update
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F22%3A00127692" target="_blank" >RIV/00216224:14110/22:00127692 - isvavai.cz</a>
Výsledek na webu
<a href="https://www.ecdc.europa.eu/sites/default/files/documents/Interim-analysis-COVID-19-vaccine-over-20.pdf" target="_blank" >https://www.ecdc.europa.eu/sites/default/files/documents/Interim-analysis-COVID-19-vaccine-over-20.pdf</a>
DOI - Digital Object Identifier
—
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to SARS-CoV-2 in individuals aged 20 years and older – third update
Popis výsledku v původním jazyce
This current report builds on previous analyses [3,4,5] and extends the age groups included. An overview of outcomes, study period and age groups included in the analysis are presented in Table 1 Previous ECDC publications on COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2, are available [3,4]. This third update contains vaccine effectiveness results among individuals aged 20 years and older for the Omicron period) for the first time as well as estimates by COVID-19 vaccine product (i.e. Comirnaty and Vaxzevria).
Název v anglickém jazyce
Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to SARS-CoV-2 in individuals aged 20 years and older – third update
Popis výsledku anglicky
This current report builds on previous analyses [3,4,5] and extends the age groups included. An overview of outcomes, study period and age groups included in the analysis are presented in Table 1 Previous ECDC publications on COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2, are available [3,4]. This third update contains vaccine effectiveness results among individuals aged 20 years and older for the Omicron period) for the first time as well as estimates by COVID-19 vaccine product (i.e. Comirnaty and Vaxzevria).
Klasifikace
Druh
O - Ostatní výsledky
CEP obor
—
OECD FORD obor
30230 - Other clinical medicine subjects
Návaznosti výsledku
Projekt
—
Návaznosti
—
Ostatní
Rok uplatnění
2022
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů